Purposes Open June 25 for Early-Stage Biotech Corporations Creating Subsequent-Era Therapeutics and Platform Applied sciences
SHANGHAI, June 25, 2026 /PRNewswire/ — ATLATL Innovation Heart (“ATLATL”), a world innovation platform for all times science analysis and improvement, and Samsung Bioepis Co., Ltd., right this moment introduced the launch of the Samsung Bioepis Innovation Prize C-Lab Exterior (Innovation Prize), an open innovation initiative designed to establish and help promising early-stage biotech corporations throughout the Asia-Pacific area.
Purposes for the Innovation Prize will open on June 25, 2026.
This system seeks revolutionary startups and rising biotech corporations working within the following therapeutic areas:
- Oncology
- Immunology & Irritation (I&I)
- Metabolic Illness
Areas of explicit curiosity embody:
- Novel/New Mechanisms of Motion (MoA)-based Antibody-Drug Conjugate (ADC)/ X-Drug Conjugates (XDC) (i.e., Payload, Linker, Conjugation)
- Antibody Engineering Expertise
- New Modality (Biologics)
- Peptide (Design Engineering, Lengthy-acting Peptide)
- Novel Goal Discovery Platform
Chosen corporations will acquire entry to ATLATL’s world-class laboratory infrastructure, entrepreneurial assets, and trade mentorship. As well as, awardees could have the chance to have interaction with Samsung Bioepis via its open innovation platform, enabling scientific collaboration, expertise evaluation, and potential future partnership alternatives. Collectively, these assets are designed to speed up innovation and help the interpretation of promising applied sciences towards commercialization.
“Innovation thrives when visionary science is matched with the proper help and alternatives,” stated Min Jeong Search engine optimisation, Vice President and Chief of Open Innovation Workforce at Samsung Bioepis. “By means of the Innovation Prize, we’re looking for to empower promising biotech entrepreneurs and researchers who’re advancing novel approaches to deal with unmet medical wants. By fostering collaboration throughout the Asia-Pacific area, we hope to assist speed up scientific innovation and contribute to a robust ecosystem for the event of future medicines.”
“Nice science alone doesn’t create profitable biotech corporations,” stated Dr. PC Zhu, Founder and CEO of ATLATL. “Innovators want entry to world-class infrastructure, R&D ecosystem, skilled mentors, strategic companions, and capital to maneuver ahead. By bringing collectively Samsung Bioepis’ international improvement experience and ATLATL’s innovation ecosystem, we hope to offer early-stage biotech entrepreneurs with the assets and help wanted to speed up innovation and ship significant influence to sufferers.”
The Samsung Bioepis Innovation Prize C-Lab Exterior displays each organizations’ dedication to advancing open innovation and supporting the subsequent technology of biotechnology entrepreneurs. By bringing collectively scientific expertise, improvement experience, and significant infrastructure, this system goals to speed up the interpretation of breakthrough analysis into transformative therapies for sufferers worldwide. The Innovation Prize can be a part of Samsung Bioepis C-Lab Exterior, Samsung Bioepis’ open innovation program designed to find, nurture, and collaborate with competent and potential biotech ventures and startups in and out of doors of Korea.
About ATLATL
As a world innovation platform for all times science analysis and improvement, ATLATL has established analysis facilities in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and different strategic places.
ATLATL gives purchasers with complete analysis and improvement companies protecting numerous phases, together with in vitro drug screening, in vivo illness mannequin institution, and efficacy analysis. ATLATL additionally helps key functions equivalent to giant molecule, small molecule, nucleic acid medication, gene and cell remedy, drug supply, in addition to cutting-edge fields like multi-omics, gene enhancing, organoids, and organ-on-a-chip. Moreover, ATLATL gives an excellent experimental setting {and professional} operational administration for scientific researchers.
By means of in-depth cooperation with main international enterprises and analysis establishments, ATLATL repeatedly integrates analysis and improvement assets and promotes the sharing of latest applied sciences. With superior systematic analysis and improvement fashions, ATLATL accelerates the engineering strategy of life sciences, enabling scientific analysis outcomes to be quickly and effectively translated into medical apply, and contributing to life science innovation and public well being on a world degree.
